BRPI0808192A2 - composto e composições como moduladores de atividades de gpr119 - Google Patents
composto e composições como moduladores de atividades de gpr119Info
- Publication number
- BRPI0808192A2 BRPI0808192A2 BRPI0808192A BRPI0808192A BRPI0808192A2 BR PI0808192 A2 BRPI0808192 A2 BR PI0808192A2 BR PI0808192 A BRPI0808192 A BR PI0808192A BR PI0808192 A BRPI0808192 A BR PI0808192A BR PI0808192 A2 BRPI0808192 A2 BR PI0808192A2
- Authority
- BR
- Brazil
- Prior art keywords
- gpr119
- modulators
- activities
- compositions
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/08—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Data Exchanges In Wide-Area Networks (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88803307P | 2007-02-02 | 2007-02-02 | |
PCT/US2008/000864 WO2008097428A2 (en) | 2007-02-02 | 2008-01-22 | Compounds and compositions as modulators of gpr119 activity |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0808192A2 true BRPI0808192A2 (pt) | 2019-09-24 |
Family
ID=39356580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0808192A BRPI0808192A2 (pt) | 2007-02-02 | 2008-01-22 | composto e composições como moduladores de atividades de gpr119 |
Country Status (15)
Country | Link |
---|---|
US (2) | US20080186971A1 (pt) |
EP (1) | EP2114890A2 (pt) |
JP (1) | JP2010518001A (pt) |
KR (1) | KR20090114428A (pt) |
CN (1) | CN101663278A (pt) |
AR (1) | AR065133A1 (pt) |
AU (1) | AU2008214440A1 (pt) |
BR (1) | BRPI0808192A2 (pt) |
CA (1) | CA2677263A1 (pt) |
CL (1) | CL2008000316A1 (pt) |
EA (1) | EA200901032A1 (pt) |
MX (1) | MX2009008159A (pt) |
PE (1) | PE20090057A1 (pt) |
TW (1) | TW200836736A (pt) |
WO (1) | WO2008097428A2 (pt) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8799466B2 (en) * | 2005-01-31 | 2014-08-05 | Hewlett-Packard Development Company, L.P. | Method and apparatus for automatic verification of a network access control construct for a network switch |
US8222261B2 (en) * | 2006-07-13 | 2012-07-17 | GlaxoSmithKline, LLC | Chemical compounds |
US9045442B2 (en) | 2007-12-21 | 2015-06-02 | University Of Notre Dame Du Lac | Antibacterial compounds and methods of using same |
JP2011513233A (ja) * | 2008-02-22 | 2011-04-28 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Gpr119活性モジュレーターとしての化合物および組成物 |
US8346697B2 (en) * | 2008-10-31 | 2013-01-01 | International Business Machines Corporation | Direct construction of finite state machines |
GB0904285D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
GB0904287D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
JP5332854B2 (ja) * | 2009-04-20 | 2013-11-06 | ソニー株式会社 | 無線送信機、無線送信方法、無線受信機および無線受信方法 |
EP2445878A1 (en) | 2009-06-24 | 2012-05-02 | Boehringer Ingelheim International GmbH | New compounds, pharmaceutical composition and methods relating thereto |
TW201113269A (en) | 2009-06-24 | 2011-04-16 | Boehringer Ingelheim Int | New compounds, pharmaceutical composition and methods relating thereto |
WO2010151711A1 (en) | 2009-06-25 | 2010-12-29 | Alkermes, Inc. | Prodrugs of nh-acidic compounds |
EP3309151A1 (en) | 2009-06-25 | 2018-04-18 | Alkermes Pharma Ireland Limited | Heterocyclic compounds for the treatment of neurological and psychological disorders |
EP2547339A1 (en) | 2010-03-18 | 2013-01-23 | Boehringer Ingelheim International GmbH | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
GB201006167D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
GB201006166D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
TW201202230A (en) * | 2010-05-24 | 2012-01-16 | Mitsubishi Tanabe Pharma Corp | Novel quinazoline compound |
WO2011153359A1 (en) | 2010-06-04 | 2011-12-08 | Albany Molecular Research, Inc. | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
AU2011270701B2 (en) | 2010-06-24 | 2015-05-14 | Alkermes Pharma Ireland Limited | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
US9512111B2 (en) | 2010-11-08 | 2016-12-06 | Lycera Corporation | N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease |
HRP20240285T1 (hr) | 2011-03-18 | 2024-05-24 | Alkermes Pharma Ireland Limited | Farmaceutski pripravci koji sadrže sorbitan estere |
CA2831334A1 (en) * | 2011-04-08 | 2012-10-11 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
US9110703B2 (en) * | 2011-06-07 | 2015-08-18 | Hewlett-Packard Development Company, L.P. | Virtual machine packet processing |
ES2715562T3 (es) | 2011-12-15 | 2019-06-04 | Alkermes Pharma Ireland Ltd | Profármacos de compuestos de amina secundaria |
CN102659675A (zh) * | 2011-12-27 | 2012-09-12 | 盛世泰科生物医药技术(苏州)有限公司 | 6-溴-2-甲基磺酰基-1,2,3,4,-四氢异喹啉的一种合成方法 |
NZ630643A (en) | 2012-03-19 | 2017-08-25 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions comprising fatty acid esters |
US9999670B2 (en) | 2012-03-19 | 2018-06-19 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
US9993556B2 (en) | 2012-03-19 | 2018-06-12 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty glycerol esters |
EP2833587A4 (en) * | 2012-03-30 | 2015-12-30 | Nec Corp | CONTROL DEVICE, COMMUNICATION DEVICE, COMMUNICATION PROCESS AND PROGRAM |
EP2834226B1 (en) | 2012-04-04 | 2016-05-25 | F.Hoffmann-La Roche Ag | 1,2-pyridazine, 1,6-pyridazine or pyrimidine-benzamide derivatives as gpbar1 modulators |
EP2847198B1 (en) | 2012-05-08 | 2016-12-14 | Lycera Corporation | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of ror-gamma and the treatment of disease |
BR112014028017A2 (pt) | 2012-05-08 | 2017-06-27 | Lycera Corp | composto, composição farmacêutica, método para tratar um distúrbio, método para reduzir a quantidade il-17 em um indivíduo e método para inibir a atividade de ror |
AR091739A1 (es) | 2012-07-11 | 2015-02-25 | Elcelyx Therapeutics Inc | Composiciones y metodos para reducir el riesgo cardiometabolico |
WO2014080285A2 (en) | 2012-09-19 | 2014-05-30 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
US20140379915A1 (en) * | 2013-06-19 | 2014-12-25 | Cisco Technology, Inc. | Cloud based dynamic access control list management architecture |
KR101984281B1 (ko) * | 2013-08-08 | 2019-05-31 | 동아에스티 주식회사 | Gpr119 작용 활성을 갖는 신규 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물 |
EP3071203B1 (en) | 2013-11-18 | 2020-12-23 | Forma Therapeutics, Inc. | Tetrahydroquinoline compositions as bet bromodomain inhibitors |
WO2015074081A1 (en) | 2013-11-18 | 2015-05-21 | Bair Kenneth W | Benzopiperazine compositions as bet bromodomain inhibitors |
US9663502B2 (en) | 2013-12-20 | 2017-05-30 | Lycera Corporation | 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease |
WO2015095795A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
WO2015095792A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease |
WO2015131035A1 (en) | 2014-02-27 | 2015-09-03 | Lycera Corporation | Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods |
BR112016021535A8 (pt) | 2014-03-20 | 2021-07-20 | Alkermes Pharma Ireland Ltd | kit compreendendo formulações de aripiprazol tendo velocidades de injeção aumentadas útil para o tratamento de uma desordem do sistema nervoso central e uso |
US9896441B2 (en) | 2014-05-05 | 2018-02-20 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
JP6523337B2 (ja) | 2014-05-05 | 2019-05-29 | リセラ・コーポレイションLycera Corporation | RORγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物 |
EP3174868B1 (en) | 2014-08-01 | 2021-08-25 | Nuevolution A/S | Compounds active towards bromodomains |
CA2962431A1 (en) | 2014-09-25 | 2016-03-31 | University Of Notre Dame Du Lac | Non-beta lactam antibiotics |
CN104447693B (zh) * | 2014-10-24 | 2016-08-24 | 苏州昊帆生物科技有限公司 | 喹啉酮衍生物及其制备方法和应用 |
CN104592215A (zh) * | 2015-01-19 | 2015-05-06 | 湖南华腾制药有限公司 | 一种哌啶取代恶二唑衍生物的制备方法 |
EP3256450B1 (en) | 2015-02-11 | 2020-12-02 | Merck Sharp & Dohme Corp. | Substituted pyrazole compounds as ror-gamma-t inhibitors and uses thereof |
CN104610390A (zh) * | 2015-02-13 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | 一种含氨基葡萄糖和腈基吡啶结构的gpr119激动剂及其用途 |
CN104610393A (zh) * | 2015-02-13 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | 一类含氨基葡萄糖和卤代吡啶结构化合物及其用途 |
CN104876918A (zh) * | 2015-04-23 | 2015-09-02 | 湖南华腾制药有限公司 | 一种吡嗪取代恶二唑化合物的制备方法 |
CN104788386A (zh) * | 2015-04-24 | 2015-07-22 | 湖南华腾制药有限公司 | 一种含氟嘧啶化合物的制备方法 |
JP2018515491A (ja) | 2015-05-05 | 2018-06-14 | リセラ・コーポレイションLycera Corporation | RORγの作動薬及び疾患の療法として使用するジヒドロ−2H−ベンゾ[b][1,4]オキサジンスルホンアミド及び関連化合物 |
MX2017016134A (es) | 2015-06-11 | 2018-08-15 | Lycera Corp | Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad. |
CN105175401A (zh) * | 2015-10-16 | 2015-12-23 | 北京康立生医药技术开发有限公司 | 一种依匹哌唑的制备方法 |
JP2018531957A (ja) | 2015-10-27 | 2018-11-01 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | RORγT阻害薬としての置換二環式ピラゾール化合物及びその使用 |
WO2017075182A1 (en) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | Substituted indazole compounds as rorgammat inhibitors and uses thereof |
EP3368535B1 (en) | 2015-10-27 | 2020-12-02 | Merck Sharp & Dohme Corp. | Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof |
AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
WO2018049404A1 (en) | 2016-09-12 | 2018-03-15 | University Of Notre Dame Du Lac | Compounds for the treatment of clostridium difficile infection |
US10404594B2 (en) | 2016-12-13 | 2019-09-03 | Oracle International Corporation | System and method for providing partitions of classification resources in a network device |
US10341242B2 (en) * | 2016-12-13 | 2019-07-02 | Oracle International Corporation | System and method for providing a programmable packet classification framework for use in a network device |
WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
JP7450534B2 (ja) | 2017-10-19 | 2024-03-15 | 帝人ファーマ株式会社 | ベンズイミダゾール誘導体及びその用途 |
ES2938863T3 (es) | 2017-12-19 | 2023-04-17 | Bristol Myers Squibb Co | Triazol azoles de ácido ciclohexilo como antagonistas de ácido lisofosfatídico (LPA) |
JP7208240B2 (ja) | 2017-12-19 | 2023-01-18 | ブリストル-マイヤーズ スクイブ カンパニー | Lpaアンタゴニストとしてのシクロヘキシル酸トリアゾールアジン |
PL3710438T3 (pl) | 2017-12-19 | 2022-01-31 | Bristol-Myers Squibb Company | Triazolowe kwasy karbamoilocykloheksylowe z n-wiązaniem jako antagoniści lpa |
AU2019230014A1 (en) | 2018-03-05 | 2020-09-17 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
US20220041572A1 (en) | 2018-09-18 | 2022-02-10 | Bristol-Myers Squibb Company | Cycloheptyl acids as lpa antagonists |
EP3852746B1 (en) | 2018-09-18 | 2023-03-29 | Bristol-Myers Squibb Company | Cyclopentyl acids as lpa antagonists |
EP3853232B1 (en) | 2018-09-18 | 2023-03-01 | Bristol-Myers Squibb Company | Oxabicyclo acids as lpa antagonists |
KR102661806B1 (ko) * | 2018-11-27 | 2024-04-30 | 삼성전자주식회사 | 디스플레이 장치의 제어 방법 및 그에 따른 디스플레이 장치 |
JP2022515990A (ja) * | 2018-12-10 | 2022-02-24 | ドライブネッツ リミテッド | 通信ネットワークにおけるトラフィックフローをモニタリングするシステム及び方法 |
CN109761990B (zh) * | 2019-01-30 | 2019-12-24 | 江西中医药大学 | 一种嘧啶并嘧啶类衍生物及其制备方法和在医药上的应用 |
US20220235027A1 (en) | 2019-06-18 | 2022-07-28 | Bristol-Myers Squibb Company | Cyclobutyl carboxylic acids as lpa antagonists |
US20220235026A1 (en) | 2019-06-18 | 2022-07-28 | Bristol-Myers Squibb Company | Triazole carboxylic acids as lpa antagonists |
MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
JP2023527315A (ja) | 2020-05-22 | 2023-06-28 | アリゴス セラピューティクス インコーポレイテッド | Pd-l1を標的とするための方法及び組成物 |
JP2023531726A (ja) | 2020-06-26 | 2023-07-25 | キャリーオペ,インク. | Ampkアクチベーター |
AU2021329259A1 (en) | 2020-08-17 | 2023-03-02 | Aligos Therapeutics, Inc. | Methods and compositions for targeting PD-L1 |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5859051A (en) * | 1996-02-02 | 1999-01-12 | Merck & Co., Inc. | Antidiabetic agents |
IL121203A (en) * | 1996-07-01 | 2001-04-30 | Lilly Co Eli | 1, 2, 3, 4-tetrahydroisoquinidines, process for their preparation and pharmaceutical compositions containing the same for treating hyperglycemia and hyperlipidemia |
US5912342A (en) * | 1997-08-12 | 1999-06-15 | Heinonen; Petri | Compounds a containing a solid support |
US5995971A (en) * | 1997-09-18 | 1999-11-30 | Micdrosoft Corporation | Apparatus and accompanying methods, using a trie-indexed hierarchy forest, for storing wildcard-based patterns and, given an input key, retrieving, from the forest, a stored pattern that is identical to or more general than the key |
EP0937723A1 (de) * | 1998-02-18 | 1999-08-25 | Roche Diagnostics GmbH | Neue Sulfonamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel |
US6562828B1 (en) * | 1998-04-10 | 2003-05-13 | Japan Tobacco Inc. | Amidine compounds |
US6658002B1 (en) * | 1998-06-30 | 2003-12-02 | Cisco Technology, Inc. | Logical operation unit for packet processing |
GB9816984D0 (en) * | 1998-08-05 | 1998-09-30 | Smithkline Beecham Plc | Novel compounds |
US6643260B1 (en) * | 1998-12-18 | 2003-11-04 | Cisco Technology, Inc. | Method and apparatus for implementing a quality of service policy in a data communications network |
US6651096B1 (en) * | 1999-04-20 | 2003-11-18 | Cisco Technology, Inc. | Method and apparatus for organizing, storing and evaluating access control lists |
JP2001247569A (ja) * | 1999-08-12 | 2001-09-11 | Japan Tobacco Inc | ピロリジン誘導体又はピペリジン誘導体及びその医薬用途 |
US7028096B1 (en) * | 1999-09-14 | 2006-04-11 | Streaming21, Inc. | Method and apparatus for caching for streaming data |
US7058728B1 (en) * | 1999-10-29 | 2006-06-06 | Nokia Corporation | Method and apparatus for initiating compression of headers of packets and refreshing the context related to the packets |
CA2324801A1 (en) * | 1999-11-10 | 2001-05-10 | Andrew Gordon Swick | Use of apo b secretion/mtp inhibitors and anti-obesity agents |
RU2256661C2 (ru) * | 1999-12-03 | 2005-07-20 | Киото Фармасьютикал Индастриз, Лтд. | Производные тетрагидроизохинолина и их соли и фармацевтическая композиция на их основе |
US6798746B1 (en) * | 1999-12-18 | 2004-09-28 | Cisco Technology, Inc. | Method and apparatus for implementing a quality of service policy in a data communications network |
US6977930B1 (en) * | 2000-02-14 | 2005-12-20 | Cisco Technology, Inc. | Pipelined packet switching and queuing architecture |
AU2001256733A1 (en) * | 2000-05-16 | 2001-11-26 | Takeda Chemical Industries Ltd. | Melanin-concentrating hormone antagonist |
US7009968B2 (en) * | 2000-06-09 | 2006-03-07 | Broadcom Corporation | Gigabit switch supporting improved layer 3 switching |
US6658458B1 (en) * | 2000-06-22 | 2003-12-02 | Cisco Technology, Inc. | Cascading associative memory arrangement |
US7051078B1 (en) * | 2000-07-10 | 2006-05-23 | Cisco Technology, Inc. | Hierarchical associative memory-based classification system |
US6952425B1 (en) * | 2000-11-14 | 2005-10-04 | Cisco Technology, Inc. | Packet data analysis with efficient and flexible parsing capabilities |
US7102009B2 (en) * | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
US6995162B2 (en) * | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US7096256B1 (en) * | 2001-02-26 | 2006-08-22 | Juniper Network, Inc. | Applying configuration group information to target configuration information |
CA2441080A1 (en) * | 2001-03-23 | 2002-10-03 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
US7002965B1 (en) * | 2001-05-21 | 2006-02-21 | Cisco Technology, Inc. | Method and apparatus for using ternary and binary content-addressable memory stages to classify packets |
US7065083B1 (en) * | 2001-10-04 | 2006-06-20 | Cisco Technology, Inc. | Method and apparatus for dynamically generating lookup words for content-addressable memories |
US6775737B1 (en) * | 2001-10-09 | 2004-08-10 | Cisco Technology, Inc. | Method and apparatus for allocating and using range identifiers as input values to content-addressable memories |
US7133914B1 (en) * | 2001-10-31 | 2006-11-07 | Cisco Technology, Inc. | Statistics-preserving ACL flattening system and method |
US7224968B2 (en) * | 2001-11-23 | 2007-05-29 | Actix Limited | Network testing and monitoring systems |
US6957215B2 (en) * | 2001-12-10 | 2005-10-18 | Hywire Ltd. | Multi-dimensional associative search engine |
CN1326519C (zh) * | 2001-12-14 | 2007-07-18 | 诺沃挪第克公司 | 化合物及其降低激素-敏感性脂肪酶活性的用途 |
US6715029B1 (en) * | 2002-01-07 | 2004-03-30 | Cisco Technology, Inc. | Method and apparatus for possibly decreasing the number of associative memory entries by supplementing an associative memory result with discriminator bits from an original set of information |
US6970971B1 (en) * | 2002-01-08 | 2005-11-29 | Cisco Technology, Inc. | Method and apparatus for mapping prefixes and values of a hierarchical space to other representations |
US7154888B1 (en) * | 2002-02-08 | 2006-12-26 | Cisco Technology, Inc. | Method for classifying packets using multi-class structures |
ES2316777T3 (es) * | 2002-02-15 | 2009-04-16 | Glaxo Group Limited | Moduladores de receptores vainilloides. |
US6871265B1 (en) * | 2002-02-20 | 2005-03-22 | Cisco Technology, Inc. | Method and apparatus for maintaining netflow statistics using an associative memory to identify and maintain netflows |
EP1482931B1 (en) * | 2002-03-05 | 2011-10-19 | TransTech Pharma, Inc. | Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage |
GB0206033D0 (en) * | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
US6867991B1 (en) * | 2003-07-03 | 2005-03-15 | Integrated Device Technology, Inc. | Content addressable memory devices with virtual partitioning and methods of operating the same |
US7236493B1 (en) * | 2002-06-13 | 2007-06-26 | Cisco Technology, Inc. | Incremental compilation for classification and filtering rules |
US7065367B2 (en) * | 2002-07-11 | 2006-06-20 | Oliver Michaelis | Interface selection in a wireless communication network |
US7065609B2 (en) * | 2002-08-10 | 2006-06-20 | Cisco Technology, Inc. | Performing lookup operations using associative memories optionally including selectively determining which associative memory blocks to use in identifying a result and possibly propagating error indications |
US7103708B2 (en) * | 2002-08-10 | 2006-09-05 | Cisco Technology, Inc. | Performing lookup operations using associative memories optionally including modifying a search key in generating a lookup word and possibly forcing a no-hit indication in response to matching a particular entry |
US7028136B1 (en) * | 2002-08-10 | 2006-04-11 | Cisco Technology, Inc. | Managing idle time and performing lookup operations to adapt to refresh requirements or operational rates of the particular associative memory or other devices used to implement the system |
US7082492B2 (en) * | 2002-08-10 | 2006-07-25 | Cisco Technology, Inc. | Associative memory entries with force no-hit and priority indications of particular use in implementing policy maps in communication devices |
DE60321207D1 (en) * | 2002-09-19 | 2008-07-03 | Lilly Co Eli | Diaryläther als opioid-rezeptor antagonisten |
CA2500115A1 (en) * | 2002-09-26 | 2004-04-08 | Warner-Lambert Company Llc | Heterocyclic substituted piperazines for the treatment of schizophrenia |
US7093092B2 (en) * | 2002-12-10 | 2006-08-15 | Isic Corporation | Methods and apparatus for data storage and retrieval |
US7577758B2 (en) * | 2002-12-20 | 2009-08-18 | Force 10 Networks, Inc. | Hardware support for wire-speed, stateful matching and filtration of network traffic |
US7043494B1 (en) * | 2003-01-28 | 2006-05-09 | Pmc-Sierra, Inc. | Fast, deterministic exact match look-ups in large tables |
WO2004078176A1 (en) * | 2003-03-03 | 2004-09-16 | F. Hoffmann-La Roche Ag | 2,5- and 2,6-substituted tetrahydroisoquinolines for use as 5-ht6 modulators |
JP4728962B2 (ja) * | 2003-05-19 | 2011-07-20 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 免疫抑制化合物および組成物 |
US7313827B2 (en) * | 2003-07-10 | 2007-12-25 | International Business Machines Corporation | Apparatus and method for analysis of conversational patterns to position information and autonomic access control list management |
US20050114700A1 (en) * | 2003-08-13 | 2005-05-26 | Sensory Networks, Inc. | Integrated circuit apparatus and method for high throughput signature based network applications |
US7080195B2 (en) * | 2003-10-22 | 2006-07-18 | Cisco Technology, Inc. | Merging indications of matching items of multiple groups and possibly associated with skip conditions to identify winning entries of particular use for implementing access control lists |
BRPI0418255A (pt) * | 2003-12-31 | 2007-04-17 | Warner Lambert Co | derivados de piperazina e piperidina n-substituìdos |
US7356663B2 (en) * | 2004-11-08 | 2008-04-08 | Intruguard Devices, Inc. | Layered memory architecture for deterministic finite automaton based string matching useful in network intrusion detection and prevention systems and apparatuses |
CA2592118C (en) * | 2004-12-23 | 2015-11-17 | Deciphera Pharmaceuticals, Llc | Urea derivatives as enzyme modulators |
WO2006073980A2 (en) * | 2005-01-06 | 2006-07-13 | Tervela, Inc. | Hardware-based messaging appliance |
TWI320783B (en) * | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
WO2006113910A2 (en) * | 2005-04-19 | 2006-10-26 | Surface Logix, Inc. | Inhibitors of microsomal triglyceride transfer protein and apo-b secretion |
WO2006122014A2 (en) * | 2005-05-10 | 2006-11-16 | Vertex Pharmaceuticals Incorporated | Bicyclic derivatives as modulators of ion channels |
WO2007050124A1 (en) * | 2005-05-19 | 2007-05-03 | Xenon Pharmaceuticals Inc. | Fused piperidine derivatives and their uses as therapeutic agents |
TWI329641B (en) * | 2005-08-31 | 2010-09-01 | Otsuka Pharma Co Ltd | (benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same |
US7499941B2 (en) * | 2005-09-05 | 2009-03-03 | Cisco Technology, Inc. | Pipeline regular expression matching |
US7790745B2 (en) * | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
CN101296906A (zh) * | 2005-10-26 | 2008-10-29 | 贝林格尔·英格海姆国际有限公司 | 具有mch拮抗活性的(杂)芳基化合物及包含这些化合物的药物 |
US7778972B1 (en) * | 2005-12-29 | 2010-08-17 | Amazon Technologies, Inc. | Dynamic object replication within a distributed storage system |
CN101502080A (zh) * | 2006-08-09 | 2009-08-05 | 高通股份有限公司 | 用于通过简化的套接字接口来支持广播/多播因特网协议包的设备和方法 |
CN103980151A (zh) * | 2006-08-09 | 2014-08-13 | 史密丝克莱恩比彻姆公司 | 作为阿片样物质受体的拮抗剂或反向激动剂的新型化合物 |
TW200825054A (en) * | 2006-10-18 | 2008-06-16 | Wyeth Corp | Quinoline compounds |
US7827190B2 (en) * | 2006-12-08 | 2010-11-02 | Pandya Ashish A | Complex symbol evaluation for programmable intelligent search memory |
-
2007
- 2007-08-27 US US11/845,696 patent/US20080186971A1/en not_active Abandoned
-
2008
- 2008-01-22 AU AU2008214440A patent/AU2008214440A1/en not_active Abandoned
- 2008-01-22 BR BRPI0808192A patent/BRPI0808192A2/pt not_active IP Right Cessation
- 2008-01-22 EP EP08713244A patent/EP2114890A2/en not_active Withdrawn
- 2008-01-22 EA EA200901032A patent/EA200901032A1/ru unknown
- 2008-01-22 WO PCT/US2008/000864 patent/WO2008097428A2/en active Search and Examination
- 2008-01-22 US US12/525,289 patent/US20100022515A1/en not_active Abandoned
- 2008-01-22 MX MX2009008159A patent/MX2009008159A/es not_active Application Discontinuation
- 2008-01-22 CA CA002677263A patent/CA2677263A1/en not_active Abandoned
- 2008-01-22 KR KR1020097018273A patent/KR20090114428A/ko active IP Right Grant
- 2008-01-22 JP JP2009548265A patent/JP2010518001A/ja active Pending
- 2008-01-22 CN CN200880010548A patent/CN101663278A/zh active Pending
- 2008-01-31 PE PE2008000230A patent/PE20090057A1/es not_active Application Discontinuation
- 2008-02-01 TW TW097104093A patent/TW200836736A/zh unknown
- 2008-02-01 CL CL200800316A patent/CL2008000316A1/es unknown
- 2008-02-01 AR ARP080100423A patent/AR065133A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2008214440A1 (en) | 2008-08-14 |
US20100022515A1 (en) | 2010-01-28 |
CA2677263A1 (en) | 2008-08-14 |
EA200901032A1 (ru) | 2010-02-26 |
TW200836736A (en) | 2008-09-16 |
AR065133A1 (es) | 2009-05-20 |
CN101663278A (zh) | 2010-03-03 |
EP2114890A2 (en) | 2009-11-11 |
US20080186971A1 (en) | 2008-08-07 |
WO2008097428A3 (en) | 2008-09-25 |
WO2008097428A2 (en) | 2008-08-14 |
KR20090114428A (ko) | 2009-11-03 |
CL2008000316A1 (es) | 2008-08-08 |
MX2009008159A (es) | 2009-10-08 |
JP2010518001A (ja) | 2010-05-27 |
PE20090057A1 (es) | 2009-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0808192A2 (pt) | composto e composições como moduladores de atividades de gpr119 | |
BRPI0908851A2 (pt) | compostos e composições como moduladores da atividades de gpr119 | |
BRPI0817211A2 (pt) | composto composições como moduladores da atividade de gpr119 | |
BRPI0907584A2 (pt) | Composto e composições como moduladores de atividade de gpr119 | |
BRPI0909037A2 (pt) | compostos e composições como moduladores da atividade de tlr | |
BRPI0911118A2 (pt) | composto e compisições como moduladores de atividade de gpr119 | |
BRPI0906980A2 (pt) | Composição de derivados e maleatados | |
BRPI0912668A2 (pt) | composto e composições como inibidores de quinase | |
BRPI0914652A2 (pt) | compostos e composições como inibidores de quinase | |
BRPI0922084A2 (pt) | Composições e métodos compreendendo variantes de serina protease | |
BRPI0915867A2 (pt) | 4-fenoximetilpiperidinas como moduladores de atividade de gpr119 | |
BRPI0810179A2 (pt) | Composições de oligo-guluronato e galacturonato | |
DK2634232T3 (da) | Sammensætninger | |
BRPI0906749A2 (pt) | Composição | |
BRPI0913808A2 (pt) | composição | |
BRPI1011587A2 (pt) | compostos e composições terapèuticas | |
BRPI0919708A2 (pt) | composições antimicrobianas | |
BRPI0908952A2 (pt) | Uso de alternan como espessante e composições espessantes contendo alternan e outro espessante | |
BRPI0913086A2 (pt) | Composições antimicrobianas e métodos de uso | |
IT1392101B1 (it) | Composizione comprendente isoflavoni | |
BRPI0917231A2 (pt) | composição | |
FI20096058A0 (fi) | Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä | |
BRPI0910979A2 (pt) | compostos e composições como inibidores de quinase | |
FR2933868B1 (fr) | Compositions cosmetiques | |
BRPI0921705A2 (pt) | Composições antimicrobianas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |